HNSPF (Hansoh Pharmaceutical Group Co) Other Current Liabilities: $397 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
91 GF Score
Price $3.83
GF Value $3.10
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Other Current Liabilities?

Hansoh Pharmaceutical Group Co HNSPF 91 Other Current Liabilities is $397 Mil as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.10 (Modestly Overvalued).

Hansoh Pharmaceutical Group Co's other current liabilities for the quarter that ended in Dec. 2025 was $397 Mil.

Hansoh Pharmaceutical Group Co's quarterly other current liabilities increased from Dec. 2024 ($207 Mil) to Jun. 2025 ($220 Mil) and increased from Jun. 2025 ($220 Mil) to Dec. 2025 ($397 Mil).

Hansoh Pharmaceutical Group Co's annual other current liabilities declined from Dec. 2023 ($222 Mil) to Dec. 2024 ($207 Mil) but then increased from Dec. 2024 ($207 Mil) to Dec. 2025 ($397 Mil).

Hansoh Pharmaceutical Group Co Other Current Liabilities Related Terms

Hansoh Pharmaceutical Group Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Other Current Liabilities Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 274.32 232.69 221.98 207.40 397.39

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.98 226.34 207.40 219.68 397.39
HNSPF
91GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $397 Mil mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Other Current Liabilities of $397 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hansoh Pharmaceutical Group Co.
Is Hansoh Pharmaceutical Group Co's Other Current Liabilities too high?
Hansoh Pharmaceutical Group Co's current Other Current Liabilities is $397 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Other Current Liabilities compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Other Current Liabilities of $397 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hansoh Pharmaceutical Group Co. Hansoh Pharmaceutical Group Co's current Other Current Liabilities is $397 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.10, compared to a current price of $3.83 — trading 23.4% above its estimated fair value. The current Other Current Liabilities is $397 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Other Current Liabilities is $397 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 23.4% above its estimated GF Value™ of $3.10. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for HNSPF:

  • Other Current Liabilities: $397 Mil
  • GF Value™: $3.10 vs. price of $3.83 (23.4% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score

Get the complete analysis for HNSPF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.10
GF Value